AccessibilityHelpAbout Us
Genex Pharmaceutical logo

Genex Pharmaceutical(OTC) GENX

Market Cap$1.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)-100%
5 Year-100%
1 Year+0%
1 Month-50%
$0.00
+0.00%
+0.00Today
Genex Pharmaceutical last closing stock price
MetricPriceDate
Last closeUSD 0.002026-05-14
Genex Pharmaceutical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-50%USD 0.002026-04-09
1 month-50%USD 0.002026-04-09
3 month+0%USD 0.002025-12-19
Year to date+0%USD 0.002025-12-19
1 year+0%USD 0.002024-10-04
3 year+0%USD 0.002023-05-15
5 year-99.66%USD 0.032021-05-14
Since inception-100%USD 3.502004-06-22

Genex Pharmaceutical Financials at a Glance

Market Cap

$1.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$3.24M

Net Income (TTM)

$342.55K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-11.09 (Low)

Price

$0.00

Volume

200

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

GENX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Genex Pharmaceutical

Genex Pharmaceutical, Inc. is a healthcare company focused on the development and production of Reconstituted Bone Xenograft, a medical device designed to accelerate bone healing. Founded in 2002 and headquartered in Tianjin, China, the company operates within the medical specialties industry.

Products and Services
  • Reconstituted Bone Xenograft for enhanced bone healing
  • Innovative medical devices targeting orthopedic applications
  • Research and development in regenerative medicine
Growth Outlook
  • Strong demand for bone healing solutions in the healthcare market
  • Expansion into new markets anticipated in the coming years
  • Investment in R&D expected to drive product innovation
Financial Highlights
  • Recent quarterly revenue of 894,787, showing growth potential
  • Net income margin of 10.58% indicates profitability
  • Operating cash flow of 5409 demonstrates operational efficiency
Genex Pharmaceutical, Inc. is positioned in a growing sector with a focus on innovative solutions for bone healing. The company's flagship product, Reconstituted Bone Xenograft, addresses a critical need in orthopedic medicine, which is expected to drive future growth. The healthcare market's increasing demand for effective bone healing solutions presents significant opportunities for expansion. Recent financial performance indicates a positive trajectory, with quarterly revenue reflecting growth and a solid net income margin. The operational efficiency, as evidenced by the operating cash flow, suggests that the company is managing its resources effectively. With ongoing investments in research and development, Genex Pharmaceutical is poised to enhance its product offerings and capture a larger market share in the medical specialties industry.
AI Generated • Sep 3, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Headquarters

Tianjin, TX 300074, CN

GENX Financials

Key Financial Metrics (TTM)

Gross Margin

88.80%

Operating Margin

14.40%

Net Income Margin

10.58%

Return on Equity

7.78%

Return on Capital

9.84%

Return on Assets

3.96%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

17.85M

Volume

200

Avg. Volume

0

Financials (TTM)

Gross Profit

$2.87M

Operating Income

$466.14K

EBITDA

$718.27K

Operating Cash Flow

$529.66K

Capital Expenditure

-$579.00

Free Cash Flow

$528.41K

Cash & ST Invst.

$430.12K

Total Debt

$0.00

Genex Pharmaceutical Performance Analysis

Genex Pharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12007-03-317.8%
Q22007-06-302.6%
Q32007-09-3014.4%
Q42007-12-314.1%
Genex Pharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12007-03-3120.5%
Q22007-06-30N/A
Q32007-09-30-67.0%
Q42007-12-31-224.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q4 2007YOY CHG

Revenue

$894.79K

+31.8%

Gross Profit

$809.19K

+25.5%

Gross Margin

90.43%

N/A

Market Cap

$1.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$20.93

N/A

Employees

86

N/A

Net Income

-$72.59K

-148.7%

EBITDA

$131.81K

+122.2%

Quarterly Fundamentals

Name
Q4 2007YOY CHG

Total Cash

$430.12K

+123.8%

Total Debt

$0.00

N/A

Accounts Receivable

$163.82K

-5.3%

Inventory

$484.84K

+5.3%

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

3.96%

N/A

Return on Invested Capital

9.01%

N/A

Free Cash Flow

$4.16K

-96.9%

Operating Cash Flow

$5.41K

-96.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CBGIThe CannaBusiness Group, Inc.
$0.00+0.00%
LTHOLegacy Technology Holdings, Inc.
$0.00+0.00%
JUVAFJuva Life Inc.
$0.00+0.00%
FIORFFiore Cannabis Ltd.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TNONTenon Medical
$5.30+1.17%
SPCXSpace Exploration Technologies
$148.18+0.00%
NVDANvidia
$218.36-0.02%
INTCIntel
$100.32-0.06%

Questions About GENX

What is the current price of Genex Pharmaceutical?

Genex Pharmaceutical is trading at $0.00 per share.

What is the 52-week range for Genex Pharmaceutical?

Over the past 52 weeks, Genex Pharmaceutical has traded between $0.00 and $0.00.

How much debt does Genex Pharmaceutical have?

Genex Pharmaceutical total debt is unavailable.

How much cash does Genex Pharmaceutical have on hand?

Genex Pharmaceutical does not have cash on hand data available.

What is Genex Pharmaceutical’s dividend yield?

Genex Pharmaceutical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services